Clinical Proteomics
News on proteomics applications for clinical use in genetics, genomics, and molecular diagnostics.
Sera Prognostics Goes Public With $75M IPO
The firm is offering 4,687,500 shares of its common stock at $16 per share. Its first commercial product is the PreTRM test for predicting the risk of a preterm birth.
The team and its partner SpectraPass are creating an assay with the intent of obtaining Emergency Use Authorization from the US Food and Drug Administration.
Sera Prognostics Raises $100M in Series E Round
The company said the money will be used in part to support the ongoing commercialization of its PreTRM preterm birth risk test.
Stella Dx, University of Kansas Medical Center Collaborate on Barrett's Esophagus Panel
The partners will assess Stella's assay by quantifying proto-oncogenes in Barrett's esophagus tissue that have progressed to cancer, and those that have not.
NanoString Technologies, OHSU Partner on Breast Cancer Spatial Protein Profiling Assay Development
A new GeoMx Digital Spatial Profiler assay will have up to 30 protein targets and will be validated for potential use as a laboratory-developed test.